0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letters |

APOE ε2/ε4 Genotype a Risk Factor for Primary Progressive Aphasia in Women FREE

Antonio Daniele, MD, PhD; Maria G. Matera, BiolD; Davide Seripa, BiolD; Adele Acciarri, MD; Alessandra Bizzarro, MD, PhD; Alberto Pilotto, MD; Carlo Masullo, MD
Arch Neurol. 2009;66(7):910-916. doi:10.1001/archneurol.2009.136.
Text Size: A A A
Published online

Frontotemporal dementia (FTD) is a clinically and pathologically heterogeneous entity characterized by focal degeneration of the cerebral cortex, which may present with behavioral and cognitive symptoms, especially linguistic deficits. Genetic factors might play an important role in FTD, which is a relatively common cause of early-onset dementia. We reported that the frequency of the ε2/ε4 genotype of the apolipoprotein E (APOE; GenBank AF286472) gene is significantly increased in primary progressive aphasia (PPA),1 one of the syndromes associated with FTD. Primary progressive aphasia is characterized by progressive language impairment, while other cognitive functions remain relatively intact for at least the first 2 years of the course.2

We examined 125 patients with a clinical diagnosis of probable FTD,3 including a subgroup of 39 patients with PPA2 and 343 age-matched controls (Table 1). Compared with controls, we observed a significant increase in ε2/ε4 genotype frequency in the overall FTD group and a highly significant increase in ε2/ε4 genotype frequency in the PPA subgroup. Compared with controls, a significant increase in ε4 allele frequency was detected in the FTD group, while a significant decrease in ε3 allele frequency was observed in the FTD group and the PPA subgroup. The APOE ε2/ε4 genotype was detected in 5 patients affected by PPA (4 women and 1 man) and in 1 woman affected by FTD not belonging to the PPA subgroup. Therefore, APOE genotype and allele frequencies were further analyzed according to sex (Table 2).

Table Graphic Jump LocationTable 1. Apolipoprotein E Genotype and Allele Frequencies in Patients Affected by FTD and in the Subgroup With PPA Compared With Controls

Table Graphic Jump LocationTable 2. Apolipoprotein E (APOE) Genotype and Allele Frequencies in Patients With FTD and in the Subgroup With PPA Compared With Controls in Men (Upper Section) and in Women (Lower Section)

In men, a significant decrease in ε3/ε3 genotype and ε3 allele frequencies and a significant increase in ε3/ε4 genotype and ε4 allele frequencies were observed in the overall group with FTD and in the PPA subgroup. Moreover, the ε4/ε4 genotype was detected only in men with FTD, with a significant increase in frequency in men with FTD.

In women, we observed a significant increase in ε2/ε4 genotype frequency in the FTD group and a highly significant increase in ε2/ε4 genotype frequency in the PPA subgroup.

The results of the present study on a larger sample of patients with FTD and controls agree with our preliminary findings,1 suggesting that the ε2/ε4 genotype might represent a genetic risk factor for PPA, while the ε3 allele might have protective effects for PPA and FTD. Moreover, the present results suggest that the ε2/ε4 genotype might represent a genetic risk factor, particularly for women with PPA. In men with FTD, by contrast, the ε3/ε3 genotype and ε3 allele might play a protective role, while ε3/ε4 genotypes and ε4 allele may increase the risk. Our findings only partially support a recent study that describes a significant increase in ε4 allele frequency and a trend toward a decrease in ε2 allele frequency in men with FTD.4

The ε2 allele might play a pathogenic role in other neurodegenerative conditions, as it might increase the risk of Parkinson disease. Patients with FTD carrying the ε4 allele show β-amyloid protein deposits more frequently than ε4 noncarriers, although β-amyloid deposition in FTD could be unrelated to primary pathological processes.5 Even if we cannot exclude the possibility that the association between ε2/ε4 genotype and PPA may be due to the insufficient size of our samples, such an association may be explained by molecular positive heterosis. When a certain chromosomal locus has 2 different alleles (for example, alleles A and B), heterozygosity occurs when a subject has both of the 2 alleles, A and B, and can be therefore defined as an AB heterozygote, while subjects having only the A or B allele can be defined as AA homozygotes and BB homozygotes, respectively. Usually, in a 2-allele polymorphism (where a single chromosomal locus has the 2 alleles, A and B), if the allele A is strongly associated with a certain phenotypic effect, subjects carrying the AA genotype (AA homozygotes) should show the greatest phenotypic effect, subjects carrying the BB genotype (BB homozygotes) should show the least phenotypic effect, and AB heterozygotes should show an intermediate phenotypic effect. Molecular positive heterosis is a counterintuitive phenomenon that occurs when subjects heterozygous for a specific genetic polymorphism (for example, AB heterozygotes) show a significantly greater phenotypic effect (positive heterosis) for a quantitative or dichotomous trait than homozygotes for either allele (AA homozygotes and BB homozygotes).6 Although the possible mechanisms involved in molecular positive heterosis are only partially known, this is a relatively common phenomenon that has been shown in several disorders and may be sex-specific, namely, it may be observed only in either men or women.6 Thus, in our series, women with the APOE ε2/ε4 genotype showed an increased risk for PPA compared with women with either ε2/ε2 or ε4/ε4 homozygosity. Further studies are needed to confirm the role of ε2/ε4 genotype as a risk factor in women with PPA and to clarify the possible pathogenic mechanisms related to APOE in this syndrome.

ARTICLE INFORMATION

Correspondence: Dr Daniele, Institute of Neurology, Catholic University, Largo A. Gemelli, 8, Rome I-00168, Italy (adaniele@rm.unicatt.it).

Author Contributions: Drs Daniele and Seripa contributed equally to this study.

Financial Disclosure: None reported.

Funding/Support: This study was partially supported by grants No. AN/F9 and Istituti di Ricovero e Cura a Carattere Scientifico Research Program, Ricerca Corrente 2006-2008, Linea No. 2 “Malattie di rilevanza sociale” from the Italian Ministry of Health.

Acciarri  AMasullo  CBizzarro  A  et al.  ApoE epsilon2-epsilon4 genotype is a possible risk factor for primary progressive aphasia. Ann Neurol 2006;59 (2) 436- 437
PubMed Link to Article
Mesulam  MM Primary progressive aphasia. Ann Neurol 2001;49 (4) 425- 432
PubMed Link to Article
McKhann  GMAlbert  MSGrossman  MMiller  BDickson  DTrojanowski  JQWork Group on Frontotemporal Dementia and Pick's Disease, Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58 (11) 1803- 1809
PubMed Link to Article
Srinivasan  RDavidson  YGibbons  L  et al.  The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in males. J Neurol Neurosurg Psychiatry 2006;77 (2) 154- 158
PubMed Link to Article
Mann  DM McDonagh  AMPickering-Brown  TKowa  HIwatsubo  T Amyloid beta protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype. Neurosci Lett 2001;304 (3) 161- 164
PubMed Link to Article
Comings  DEMacMurray  JP Molecular heterosis: a review. Mol Genet Metab 2000;71 (1-2) 19- 31
PubMed Link to Article

Figures

Tables

Table Graphic Jump LocationTable 1. Apolipoprotein E Genotype and Allele Frequencies in Patients Affected by FTD and in the Subgroup With PPA Compared With Controls
Table Graphic Jump LocationTable 2. Apolipoprotein E (APOE) Genotype and Allele Frequencies in Patients With FTD and in the Subgroup With PPA Compared With Controls in Men (Upper Section) and in Women (Lower Section)

References

Acciarri  AMasullo  CBizzarro  A  et al.  ApoE epsilon2-epsilon4 genotype is a possible risk factor for primary progressive aphasia. Ann Neurol 2006;59 (2) 436- 437
PubMed Link to Article
Mesulam  MM Primary progressive aphasia. Ann Neurol 2001;49 (4) 425- 432
PubMed Link to Article
McKhann  GMAlbert  MSGrossman  MMiller  BDickson  DTrojanowski  JQWork Group on Frontotemporal Dementia and Pick's Disease, Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58 (11) 1803- 1809
PubMed Link to Article
Srinivasan  RDavidson  YGibbons  L  et al.  The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in males. J Neurol Neurosurg Psychiatry 2006;77 (2) 154- 158
PubMed Link to Article
Mann  DM McDonagh  AMPickering-Brown  TKowa  HIwatsubo  T Amyloid beta protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype. Neurosci Lett 2001;304 (3) 161- 164
PubMed Link to Article
Comings  DEMacMurray  JP Molecular heterosis: a review. Mol Genet Metab 2000;71 (1-2) 19- 31
PubMed Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

698 Views
7 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs